

Functional Characterization of Cardiac Isoform of Alpha 2 Macroglobulin (CA2M): Identification of Non-Hypertrophic Domain

¹Subbiah Ramasamy, ²Pitchai Balakumar, ³Manjeet Singh, ^{1,4}Andiappan Rathinavel,

¹Koteshwara Ananthamurthy, ¹Tharmarajan Ramprasath and ¹Govindan Sadasivam Selvam

¹Department of Biochemistry and Microbial Gene Technology, School of Biological Sciences, Madurai Kamaraj University, Madurai, Tamilnadu, India

²Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India

³I.S.F. Institute of Pharmaceutical Sciences and Drug Research, Moga, Punjab, India

⁴Department of Cardio-Thoracic Surgery, Madurai Medical College and Government Rajaji Hospital, Madurai, India

Abstract: Gene therapy is an emerging strategy for the treatment of cardiovascular disorders. However, the efficient vehicle for gene delivery into myocardium is inadequately available to treat cardiovascular disorders. Despite the fact that many non-invasive protocols are used in gene delivery, the *in vivo* gene transfer into the heart is less specific and toxic. Therefore, alternative safe targeting methods are needed to deliver the specific gene into myocardium. In the present study, we developed an efficient method of gene transfer using nonhypertrophic receptor binding domain of Cardiac isoform of Alpha 2 Macroglobulin (CA2M) into myocardium. CA2M is a serum marker protein, which is cardiac specific and induced during hypertrophy in rats. *In vivo* gene transfer by direct injection of the truncated forms of CA2M into myocardium was performed in rats. The expression study using western blotting and quantification-using sandwich ELISA have identified the Nonhypertrophic Receptor-Binding Domain (NhrBD) of CA2M. Thus, the NhrBD of CA2M may be used as a novel vehicle to deliver the therapeutic gene into myocardium.

Key words: CA2M, NhrBD, vehicle for cardiac gene delivery, functional characterization, non-hypertrophic domain

INTRODUCTION

Cardiac gene therapy holds as a potential molecular therapeutic approach for treating cardiovascular abnormalities (Williams *et al.*, 2004). The vehicles used for targeted cardiac gene delivery such as adenoviral and c-type based viral vectors have been associated with cytotoxicity and triggering immune responses and thus limit their application (Wickham, 2000; George, 2003). Therefore, cardiac specific and non-toxic vehicles are required to be developed for cardiac gene transfer efficiently. Earlier studies from our laboratory has identified a novel high molecular weight serum protein of 182-kDa as Cardiac isoform of Alpha 2 Macroglobulin (CA2M) and suggested to be a specific biomarker of cardiac hypertrophy in rats and humans (Mariappan *et al.*, 1994; Rajamanickam *et al.*, 1998). Our further studies have suggested, that CA2M could be used as a diagnostic marker for cardiac diseases (Rathinavel *et al.*, 2005). Moreover, our recent studies have confirmed that CA2M is a novel biomarker for cardiac disorders in patients with

diabetes and HIV/AIDS (Annapoorani *et al.*, 2006; Ramasamy *et al.*, 2006). Since, CA2M is cardiac specific in nature; the nonhypertrophic domain of CA2M may be a potential vehicle for cardiac gene transfer. Therefore, the present study has been undertaken to explore the non-hypertrophy inducing functional domains of CA2M to develop the novel vehicles for transferring the therapeutic genes into myocardium.

MATERIALS AND METHODS

Pressure overload-induced cardiac hypertrophy in rats:

The Institutional Animal Ethical Committee approved the experimental protocol used in the present study. Young Wistar albino rats were used in present study. Six groups were employed in present study and each group comprising of 8-10 animals. The pressure overload-induced cardiac hypertrophy in rats was produced using aortic banding for 21 days (Mariappan *et al.*, 1994). The sham-operated animals were subjected to same surgical procedures except aortic constriction.

Cloning and sequencing of N-terminal, middle fragment and C-terminal Receptor Binding Domain (RBD) of CA2M:

The primers for functional specific domains of CA2M were designed. The N-terminal primers are 5'GCATGCGGGAAGCACAG3'(sense)and5'CCATGGACAGACTCCAAGGA3' (antisense), middle fragment primers are 5'TAACCATGGG TCCAGAGACAA3'(sense) and 5'GTCGACTCAGGCATTTCCATA5'(antisense) and C-terminal RBD primers are 5'CGCGCATGCATGCCCTATGGCTGTGGAGAA CAG3'(sense) and 5'GCTGTCGACTCAGGCATTTCCATAATCTGTGCTG3'(antisense). The PCR protocols include denaturation at 94°C for 30 sec followed by annealing at 58°C for 50 sec and extension at 72°C for 60 sec. Thirty five cycles of reactions were performed with an initial denaturation for 4 min and followed by final extension at 72°C for 7 min. The resulting PCR products were resolved on 2% agarose gel. The three PCR yielded products were initially cloned in p-GEM-T Easy vector (Promega, Madison, USA). Using Not I restriction site they were transferred into pcDNA3.1(-) (Invitrogen, USA), a mammalian expression vector. The sequences for N-terminal, middle fragment and C-terminal RBD of CA2M were analyzed and submitted to NCBI Genbank under accession number of AY919611, AY921651 and AY887133, respectively.

Preparation of plasmid dna for injection: The plasmid DNA was prepared using the column method (Plasmid mini kit- Qiagen, Heidelberg, Germany). For injection, 100 µg of plasmid DNA was suspended in 100 µL of normal saline. The functional specific domain constructs of CA2M in pcDNA3.1(-) were injected into myocardium of normal rats to assess the development of cardiac hypertrophy. The full-length CA2M in pcDNA3.1(-) vector was used as a positive control. The animals were sacrificed at end of 3 weeks and the ratio of left ventricular weight to body weight (mg g⁻¹) (Balakumar and Singh, 2006a, b) and CA2M level (Mariappan *et al.*, 1994) were measured to assess the development of cardiac hypertrophy.

Western blot analysis and quantification of CA2M levels using sandwich ELISA: The CA2M from the serum of rats was purified and anti-rat CA2M antiserum was raised as previously described (Harlow and Lane, 1998; Rajamanickam *et al.*, 1998). The immuno-cross reactivity between rat CA2M and anti-rat CA2M antibody was tested by western blot analysis and the quantification of CA2M level was carried out using sandwich ELISA.

Statistical analysis: Results were expressed as mean±S.E.M. The data obtained from various groups were statistically analyzed using one-way ANOVA followed by post hoc analysis using Tukey's multiple range test. A p value <0.05 was considered to be statistically significant.

RESULTS

The LVW/BW ratio and CA2M level were found to be high in aortic-constricted group when compared with sham group. This result indicates that cardiac hypertrophy has been developed in aortic constricted rats. Moreover, the LVW/BW ratio and CA2M level were observed to be increased in rats subjected to cardiac injection of full-length cDNA of CA2M, N-Terminal




Fig. 1: Bar diagram shows the ratio of left ventricular weight to body weight (mg g⁻¹). Results were expressed as mean ± SEM. AC indicates aortic constricted; NTR indicates N-terminal region; MFR indicates middle fragment region and RBD indicates receptor-binding domain. a = p<0.05 Vs sham control; b = p<0.05 Vs AC control; c = p<0.05 Vs full length cDNA of CA2M injected group




Fig. 2: Bar diagram shows the levels of Cardiac isoform of Alpha 2 Macroglobulin (CA2M) in various groups. Results were expressed as mean ± SEM. AC indicates aortic constricted; NTR indicates N-terminal region; MFR indicates middle fragment region and RBD indicates receptor-binding domain. a = p<0.05 Vs sham control; b = p<0.05 Vs AC control; c = p<0.05 Vs full length cDNA of CA2M injected group

Table 1: Shows the ratio of left ventricular weight to body weight (mg g^{-1}) and ELISA values of Cardiac isoform of Alpha 2 Macroglobulin (CA2M) in various groups. Results were expressed as mean \pm SEM. AC indicates aortic constricted; NTR indicates N-terminal region; MFR indicates middle fragment region and RBD indicates receptor-binding domain. a = $p < 0.05$ Vs sham control; b = $p < 0.05$ Vs AC control; c = $p < 0.05$ Vs full length cDNA of CA2M injected group

	Sham control	AC control	Full length cDNA of CA2M injected	NTR of CA2M injected	MFR of CA2M injected	RBD of CA2M injected
LVW/BW (mg g^{-1})	1.97 \pm 0.06	2.78 \pm 0.03 ^a	2.86 \pm 0.072 ^a	2.71 \pm 0.081 ^a	2.7 \pm 0.043 ^a	2.06 \pm 0.071 ^{b,c}
CA2M (mg dL^{-1})	49.2 \pm 2.9	93.7 \pm 3.6 ^a	112.6 \pm 2.3 ^a	97.1 \pm 2.72 ^a	82.8 \pm 3.54 ^a	53.3 \pm 2.78 ^{a,c}

Region (NTR) of CA2M and growth factor encoded Middle Fragment Region (MFR) of CA2M. It further shows, that cardiac hypertrophy has been developed in these groups. On the other hand, no cardiac hypertrophy has been developed in rats injected with RBD of CA2M since the LVW/BW ratio and CA2M level were not altered when compared with sham group (Fig. 1 and 2). The ratio of left ventricular weight to body weight (mg g^{-1}) and ELISA values of Cardiac isoform of Alpha 2 Macroglobulin (CA2M) obtained from various groups were summarized in Table 1.

DISCUSSION

Gene therapy is an emerging strategy for the treatment of cardiovascular disorders (Isner and Losordo, 1999). The adenoviral and c-type based vectors have been currently employed in targeted gene delivery into myocardium (Wickham, 2000). However, their applications have not been satisfactory due to their less efficiency and more toxicity (George, 2003). Moreover, these vectors have been noted to trigger immune responses (Wickham, 2000; Roth *et al.*, 2002). Therefore, developing novel non-viral vehicles for cardiac specific gene transfer without producing toxicity and immune responses would be a clinically mandatory one in cardiovascular therapeutics. In the present study, we have demonstrated that the Nonhypertrophic Receptor-Binding Domain (NhRBD) of CA2M may be used as a novel vehicle for gene delivery into myocardium. Earlier study in our laboratory has shown that CA2M is an early diagnostic marker of cardiac hypertrophy (Mariappan *et al.*, 1994; Rajamanickam *et al.*, 1998). Further, our laboratory has reported that *in vivo* administration of purified protein of CA2M or cDNA of CA2M has induced cardiac hypertrophy in rats (Rajamanickam *et al.*, 2001; Rajan *et al.*, 2003). Moreover, *in vivo* administration of polyclonal antibody raised against CA2M abolished the development of cardiac hypertrophy by down regulating the expression of beta-MHC and MLC-2 in rats (Rajamanickam *et al.*, 2001). Recently, we have confirmed that CA2M is a novel diagnostic marker for all cardiac diseases and a new biomarker for myocardial infarcted diabetic patients (Rathinavel *et al.*, 2005; Annapoorani *et al.*, 2006). Finally, we have suggested that CA2M is a cardiac specific protein and strongly shown that CA2M is an early diagnostic marker for

cardiac manifestations in AIDS patients (Ramasamy *et al.*, 2006). The results obtained in the present study have pointed out the fact that the receptor-binding domain of CA2M is a non-hypertrophic domain. Since CA2M is cardiac specific in nature, the Nonhypertrophic Receptor-Binding Domain (NhRBD) of CA2M could be exploited non-invasively to target and specifically express genes of our interest into myocardium. Further, a study exploring the functional characterization and applications of NhRBD of CA2M as a novel vehicle for cardiac gene transfer is currently underway.

REFERENCES

- Annapoorani, P., P.S. Dhandapany, S. Sadayappan, S. Ramasamy, A. Rathinavel and G.S. Selvam, 2006. Cardiac isoform of alpha-2 macroglobulin-A new biomarker for myocardial infarcted diabetic patients. *Atherosclerosis*, 186: 173-176.
- Balakumar, P. and M. Singh, 2006a. Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats. *Pharmacology*, 78: 91-97.
- Balakumar, P. and M. Singh, 2006b. The possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. *Basic. Clin. Pharmacol. Toxicol.*, 99: 418-424.
- Harlow, E. and D.P. Lane, 1988. *Antibodies-a laboratory manual*. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press.
- Isner, J.M. and D.W. Losordo, 1999. Therapeutic angiogenesis for heart failure. *Nat. Med.*, 5: 491-492.
- Mariappan, M., N. Selvamurgan and C. Rajamanickam, 1994. Purification and characterization of a high molecular weight protein induced in rat serum during the development of cardiac hypertrophy. *Arch. Biochem. Biophys.*, 315: 558.
- Rajamanickam, C., S. Sakthivel, G. Jegadeesh Babu, F. Lottspeich and B. Kadenbach, 2001. Cardiac isoform of alpha-2 macroglobin, a novel serum protein, may induce cardiac hypertrophy in rats. *Basic Res. Cardiol.*, 96: 23-33.
- Rajamanickam, C., S. Sakthivel, P.K. Joseph and R.A. Janarthanan, 1998. A novel serum protein of molecular weight 182 kDa: A molecular marker for an early detection of increased left ventricular mass in patients with cardiac hypertrophy. *J. Cardiovas. Risk.*, 5: 335-338.

- Rajan, S., J. Radhakrishnan and C. Rajamanickam, 2003. Direct injection and expression *in vivo* of full-length cDNA of the cardiac isoform of alpha-2 macroglobulin induces cardiac hypertrophy in the rat heart. *Basic. Res. Cardiol.*, 98: 39-49.
- Ramasamy, S., R. Omnath, A. Rathinavel, P. Kannan, P.S. Dhandapany, P. Annapoorani, P. Balakumar, M. Singh, R. Ganesh and G.S. Selvam, 2006. Cardiac isoform of alpha 2 macroglobulin, an early diagnostic marker for cardiac manifestations in AIDS patients. *AIDS.*, 20: 1979-1981.
- Rathinavel, A., P.S. Dhandapany, P. Annapoorani, S. Ramasamy and G.S. Selvam, 2005. Cardiac isoform of alpha-2 macroglobulin as a novel diagnostic marker for cardiac diseases. *Eur. J. Cardiovasc. Prev. Rehabil.*, 12: 601-603.
- Roth, M.D., Q. Cheng, A. Harui, S.K. Basak, K. Mitani, T.A. Low and S.M. Kiertscher, 2002. Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses. *J. Immunol.*, 169: 4651-4656.
- St George, J.A., 2003. Gene therapy progress and prospects; adenoviral vectors. *Gene. Ther.*, 10: 1135-1141.
- Wickham, T.J., 2000. Targeting adenovirus. *Gene. Ther.*, 7: 110-114.
- Williams, M.L., J.A. Hata, J. Schroder, E. Rampersaud, J. Petrofski, A. Jakoi, C.A. Milano and W.J. Koch, 2004. Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts. *Circulation*, 109: 1590-1593.